Neurocrine CEO Kevin Gorman said the deal with Xenon strengthens Neurocrine’s growing pipeline. Photo courtesy of Jamie Scott Lytle.

Neurocrine CEO Kevin Gorman said the deal with Xenon strengthens Neurocrine’s growing pipeline. Photo courtesy of Jamie Scott Lytle.

Neurocrine Biosciences has plunked down $50 million upfront for a potential epilepsy treatment, the San Diego company’s second major licensing deal this year...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $129